[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xencor, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":186},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,78,104,137,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100563732","phase-1-study-of-xmab942-in-healthy-participants-and-participants-with-ulcerative-colitis-100563732",false,"NCT06619990","Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants With Moderate-To-Severe Active Ulcerative Colitis.","Inclusion Criteria:\n\nParts A and B\n\n* Age 18-55\n* Must be in good health with no significant medical history\n* Clinical laboratory values within normal range\n* BMI 18-35 (inclusive)\n* Contraceptive use by men or women consistent with local regulations\n* Able and willing to provide written informed consent\n\nPart C\n\n* Age 18-75\n* Must be in good health with no significant medical history\n* UC diagnosis ≥ 3 months prior to screening\n* Diagnosis of moderately to severely active UC as defined by a (MMS) ≥ 5, with a MES ≥ 2 and RBS ≥ 1\n* Evidence of UC extending ≥ 15 cm from the anal verge, as determined by screening colonoscopy\n* Must have inadequate response to, loss of response to, or intolerance to at least 1 of the conventional or advanced therapies of UC\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\nParts A and B\n\n* Any physical or psychological condition that prohibits study completion\n* History of suicidal behavior or suicidal ideation\n* Heavy use of nicotine containing products\n* HIV, hepatitis B and hepatitis C positive\n* Cardiac arrhythmia, or clinically significant abnormal ECG\n* Active use of prescription medications within 14 days of Day -1\n* Active use of over-the-counter, or herbal medication within 7 days of Screening\n* Other investigational products within 30 days\n* Blood or plasma donation within 60 days\n* Pregnant or breastfeeding\n\nPart C\n\n* Any physical or psychological condition that prohibits study participation\n* Diagnosis of Crohn disease, indeterminate colitis, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis.\n* Positive screen for Clostridium difficile (C. Difficile) toxins\n* HIV, hepatitis B and hepatitis C positive\n* Cardiac arrhythmia, or clinically significant abnormal ECG\n* Pregnant or breastfeeding\n\nOther protocol defined inclusion\u002Fexclusion criteria apply.",true,"ALL","18 Years","75 Years",{"count":21,"type":22},270,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).",[29],"Ulcerative Colitis (UC)",[31,32,33],"Ulcerative Colitis","Inflammatory Bowel Disease","Healthy Volunteers","RECRUITING","2026-06-10",{"date":37,"type":38},"2026-06-11","ACTUAL",{"date":40,"type":38},"2024-10-10",{"date":42,"type":22},"2029-01",{"name":44,"class":45},"Xencor, Inc.","INDUSTRY",66,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100537335","phase-1-phase-1-safety-and-tolerability-study-of-xmab541-in-advanced-solid-tumors-100537335","NCT06276491","Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors","A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 years. For US only: subjects with GCTs, age ≥15 years\n* CLDN6+ tumor\n* Histological or cytological documentation of locally advanced, recurrent, or metastatic ovarian, fallopian tube, or peritoneal cancer, adenocarcinoma of the endometrium (endometrial cancer, uterine cancer, or carcinoma of the uterine corpus), GCT resistant to previous treatment\n* Adequate Eastern Cooperative Oncology Group performance status\n* Life expectancy ≥ 3 months\n* Adequate liver, kidney, and bone marrow function\n\nKey Exclusion Criteria:\n\n* Patients with treated brain metastases may participate, provided they are radiologically stable.\n* Active known or suspected autoimmune disease\n* Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug\n* Clinically significant cardiovascular, pulmonary or gastrointestinal disease\n* Active hepatitis B or hepatitis C","15 Years",{"count":56,"type":22},282,[25],"The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.",[60,61,62,63,64],"Ovarian Cancer","Endometrial Cancer","Germ Cell Tumor","Testicular Germ Cell Tumor","Ovarian Germ Cell Tumor",[66,60,67,68,62,61,69],"Phase 1","CLDN6","Testicular Cancer","T-cell Engager","2026-06-09",{"date":37,"type":38},{"date":73,"type":38},"2024-04-04",{"date":75,"type":22},"2028-12",{"name":44,"class":45},18,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":102,"locationsCount":103},"100472535","phase-1-study-of-xmab819-in-subjects-with-advanced-clear-cell-renal-cell-carcinoma-100472535","NCT05433142","Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma","A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n* Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by the local site investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n* Subjects who have relapsed and refractory ccRCC, pRCC, NSCLC, and CRC with evidence of disease progression on standard-of-care therapies\n* ECOG performance status of 0 or 1.\n* All subjects must have adequate tumor sample available (slides or archival FFPE blocks)\n\nExclusion Criteria:\n\n* Prior treatment with an investigational anti-ENPP3\u002FCD203c therapy\n* History of serious allergic or anaphylactic\u002Fhypersensitivity reaction to monoclonal antibody therapy\n* Systemic antineoplastic therapy within 5 half-lives on the first dose of study treatment.\n* Failure to recover from any clinically significant toxicity related to previous anticancer treatment\n* Have known active central nervous system metastases and\u002For carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable,\n* Active known autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and nonsteroidal anti-inflammatory drugs)\n* Evidence of any serious infection requiring IV anti-infective treatment within 14 days prior to the first dose of study drug\n* Have a known additional malignancy that is progressing or has required active treatment within the past 2 years",{"count":86,"type":22},307,[25],"The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).",[90],"Clear Cell Renal Cell Carcinoma",[92,93,94,95,96,97],"Clear cell Papillary","RCC","Renal Cell Cancer","Kidney Cancer","Lung Cancer","Colon Cancer",{"date":37,"type":38},{"date":100,"type":38},"2022-06-13",{"date":75,"type":22},{"name":44,"class":45},26,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100614838","phase-1-a-phase-1-open-label-study-to-evaluate-safety-in-healthy-participants-and-participants-with-autoimmune-diseases-100614838","NCT07284797","A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases","A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of XmAb657 in Healthy Participants and in Participants With Autoimmune Diseases","Inclusion Criteria:\n\nHealthy participants - Adult participants in good health\n\nIdiopathic inflammatory myopathy (IIM) participants - Adult participants that meet the 2017 European Alliance of Association Rheumatology (EULAR)\u002FAmerican College of Rheumatology (ACR) Classification Criterion for IIM\n\nSystemic sclerosis (SSc) participants - Adult participants that meet the 2013 ACR\u002FEULAR Classification Criteria for SSc\n\nSjogren's Disease participants that meet the 2016 ACR\u002FEULAR Classification Criteria for Primary Sjogren's Syndrome\n\nAll participants - Use of highly effective methods of contraception\n\nExclusion Criteria:\n\n* Major surgery within 12 weeks prior to dosing or planned within the study\n* Recurrent infections or active clinically significant infection\n* Active or untreated latent tuberculosis\n* Cancer or history of cancer or lymphoproliferative disease within the previous 5 years\n* Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease\n\nNote: Additional, more specific inclusion\u002Fexclusion criteria are defined in the protocol.",{"count":112,"type":22},60,[25],"The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.",[116,117,118,119],"Healthy","Idiopathic Inflammatory Myopathies","Systemic Sclerosis","Sjögren's Disease",[121,122,123,124,125,126,127],"Myopathy","Myositis","Scleroderma","Autoimmune Diseases","IIM","SjD","SSc","2026-05-20",{"date":130,"type":38},"2026-05-22",{"date":132,"type":38},"2026-02-24",{"date":134,"type":22},"2028-10",{"name":44,"class":45},1,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":144,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":160,"locationsCount":161},"100640634","phase-1-phase-1-safety-and-tolerability-study-of-xmab541-and-xmab808-in-advanced-solid-tumors-100640634","NCT07593092","Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors","A Phase 1 Trial, Evaluating the Safety and Tolerability of XmAb541 in Combination With XmAb808 in Advanced Solid Tumors","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* CLDN6+ tumor\n* Histological or cytological documentation of locally advanced, recurrent, or metastatic high grade serous ovarian carcinoma (HGSOC) including fallopian tube or primary peritoneal origin\n* Adequate Eastern Cooperative Oncology Group performance status\n* Life expectancy ≥ 3 months\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior exposure to a CLDN6 targeting immune cell engager\n* Patients with treated brain metastases may participate, provided they are radiologically stable.\n* Active known or suspected autoimmune disease\n* Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug\n* Clinically significant cardiovascular, pulmonary or gastrointestinal disease\n* Active viral hepatitis B or hepatitis C","FEMALE",{"count":146,"type":22},90,[25],"The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor outcomes.",[60],[66,60,151,152],"HGSOC","B7H3","NOT_YET_RECRUITING","2026-05-11",{"date":156,"type":38},"2026-05-18",{"date":158,"type":22},"2026-06",{"date":75,"type":22},{"name":44,"class":45},9,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":185},"100610651","phase-1-a-phase-1b-open-label-study-to-evaluate-safety-of-plamotamab-in-participants-with-rheumatoid-arthritis-100610651","NCT07230353","A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis","A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis","Inclusion Criteria: Adult participants with moderately to severely active RA.\n\n* Documented diagnosis of RA and meeting the 2010 American College of Rheumatology\u002FEuropean Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening\n* Inadequate response to, loss of response to, or intolerance to available RA therapies.\n* Stable doses of RA medications prior to screening\n* Use of highly effective methods of contraception\n\nExclusion Criteria:\n\n* Major surgery within 12 weeks prior to screening or planned within 12 months after dosing\n* Recurrent infections or active clinically significant infection\n* Active or untreated latent tuberculosis\n* Cancer or history of cancer or lymphoproliferative disease within the previous 5 years\n* Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease\n\nNote: Additional, more specific inclusion\u002Fexclusion criteria are defined in the protocol.",{"count":170,"type":22},68,[25],"The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.",[174],"Rheumatoid Arthritis",[176],"Rheumatoid Arthritis, Arthritis Rheumatoid, Arthritis","2026-04-09",{"date":179,"type":38},"2026-04-14",{"date":181,"type":38},"2025-10-21",{"date":183,"type":22},"2028-06",{"name":44,"class":45},3,""]